Retatrutide vs Semaglutide
These are not equivalent in evidence Semaglutide is rated 5/5 and Retatrutide is rated 3/5 — a gap of 2 levels on our scale. Similar marketing does not mean similar proof.
| Retatrutide In Clinical Trials | Semaglutide FDA Approved | |
|---|---|---|
| Evidence rating |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
|
5/5 Very strong
Evidence rating 5 out of 5: Very strong
|
| Regulatory status | Phase 3 (TRIUMPH program). Not approved anywhere. Widely and illegally sold grey-market. | FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction in obesity |
| Category | Metabolic & Weight | Metabolic & Weight |
| Drug class | Triple GLP-1 / GIP / glucagon receptor agonist | GLP-1 receptor agonist — 31-amino-acid acylated analog of human GLP-1 |
| Route | Subcutaneous, once weekly (investigational) | Subcutaneous, once weekly (oral tablet daily formulation also marketed) |
| Half-life | ~6 days | ~7 days (fatty-acid acylation drives albumin binding) |
| Sequence length | 39 residues | 31 residues |
| Molecular weight | 4,731.4 Da | 4,113.6 Da |
| Studied in | Phase 2 obesity and type 2 diabetes trials; phase 3 TRIUMPH trials ongoing across obesity, diabetes, knee osteoarthritis and sleep apnea. | STEP program (obesity), SUSTAIN program (type 2 diabetes), SELECT (cardiovascular outcomes), STEP-HFpEF (heart failure with preserved ejection fraction), FLOW (diabetic kidney disease). |
| Who should avoid it |
|
|
| Legal status | Investigational. Not approved by FDA, EMA, or any comparable regulator. Sale for human use is unlawful; "research chemical" labelling does not change that. | Prescription drug. Compounded versions are permitted only under specific FDA conditions, which have narrowed as shortages resolved. Peptides sold online as "research semaglutide" are unapproved and unverified. |
Benefits — Retatrutide
- Largest reported pharmacologic weight loss
Phase 2 data showed roughly 24% mean body-weight reduction at 48 weeks on the highest dose, with weight curves that had not yet plateaued.
- Marked hepatic fat reduction
A sub-study reported near-complete normalization of liver fat content in most participants with steatosis.
- Increased energy expenditure
The glucagon component adds a thermogenic mechanism absent from GLP-1-only drugs, in principle limiting metabolic adaptation.
Benefits — Semaglutide
- Substantial, durable weight loss
In the 68-week STEP 1 trial, adults without diabetes lost roughly 15% of body weight on 2.4 mg weekly versus about 2.4% on placebo — a magnitude previously seen only with bariatric surgery.
- Strong glycemic control
HbA1c reductions on the order of 1.5–1.8 percentage points across the SUSTAIN trials, with low intrinsic hypoglycemia risk because insulin release is glucose-dependent.
- Cardiovascular event reduction
The SELECT trial in patients with obesity and established cardiovascular disease but no diabetes showed roughly a 20% relative reduction in major adverse cardiovascular events.
- Kidney outcome benefit
The FLOW trial in diabetic kidney disease was stopped early for efficacy on a composite kidney endpoint.
- Symptom relief in HFpEF
STEP-HFpEF showed clinically meaningful improvement in heart-failure symptom scores and 6-minute walk distance in obesity-related HFpEF.
Risks & cons — Retatrutide
- No phase 3 safety data yet
Every claim about long-term safety is extrapolation. Approval is not guaranteed and prior obesity drugs have failed at exactly this stage.
- Dose-dependent heart-rate increase
Phase 2 showed increases in heart rate that peaked mid-trial. Cardiovascular outcome data do not yet exist.
- Glucose elevation potential
Glucagon agonism can raise hepatic glucose output; net glycemic effect depends on the balance with incretin activity.
- Severe GI effects at high doses
Nausea and vomiting were the dominant adverse events and drove discontinuations.
- Entirely unregulated supply
All retatrutide sold to consumers is illicit. There is no verified identity, purity, sterility, or dose accuracy, and no recourse if harmed.
Risks & cons — Semaglutide
- Gastrointestinal intolerance
Nausea, vomiting, diarrhea and constipation affect a large minority of users — the single most common reason for stopping. Slow titration mitigates but does not eliminate it.
- Thyroid C-cell tumor boxed warning
Rodents developed medullary thyroid tumors. Human relevance is unproven, but the drug is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
- Pancreatitis and gallbladder disease
Acute pancreatitis is uncommon but reported. Rapid weight loss raises the rate of cholelithiasis and cholecystitis.
- Loss of lean mass
A meaningful share of total weight lost is fat-free mass. Resistance training and adequate protein intake are standard mitigation, not optional extras.
- Delayed gastric emptying and anesthesia risk
Retained gastric contents have prompted anesthesia societies to issue pre-procedural fasting and withholding guidance because of aspiration risk.
A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.